comparemela.com
Home
Live Updates
Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC : comparemela.com
Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC
Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.
Related Keywords
United States ,
Saclay ,
France General ,
France ,
Villejuif ,
Benjamin Besse ,
Institut Gustave Roussy ,
Christabel Wilson ,
Merck Sharp Dohme ,
Genzyme Corporation ,
Oncology Congress ,
Astrazeneca ,
Merck Co Inc ,
Gustave Roussy Cancer Center ,
Paris Saclay University ,
Amgen ,
Eastern Europe ,
Western Europe ,
Taiho Oncology ,
Turning Point ,
Merck Sharp ,
Blue Bell ,
Phase 3 Pearls Keynote 091 Trial ,
Adjuvant Treatment With Pembrolizumab ,
Disease Free Survival ,
Patients With Resected Early Stage Nsclc ,
comparemela.com © 2020. All Rights Reserved.